GSK rebounds in Q1

Wednesday 4 May 2022

United Kingdom

GlaxoSmithKline Plc delivered a 32% increase in turnover to £9.8 billion in the first quarter of 2022 on the back of a double-digit rise in sales of oncology medicines and a rebound in demand for Shingrix, its vaccine for shingles. Shingrix’s sales were £698 million, or 42% of all vaccine sales in the quarter. Demand for the vaccine had flagged during the pandemic but started to recover in the new year.